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Key points 27 
• First-in-class MIR17PTi enables a “one shot” downregulation of the entire miR-28 
17-92 cluster in vitro and in vivo, with favorable PK profile. 29 
• MIR17PTi affects homeostatic MYC / miR-17-92 feedforward loops in MM cells, 30 
resulting in a strong anti-MM activity. 31 
 32 
Abstract 33 
The microRNA cluster miR-17-92 is oncogenic and represents a valuable therapeutic 34 
target in c-MYC (MYC)-driven malignancies. Here, we developed novel LNA gapmeR 35 
antisense oligonucleotides (ASOs) to induce RNase H-mediated degradation of MIR17HG 36 
primary transcripts and, consequently, to prevent biogenesis of miR-17-92 microRNAs 37 
(miR-17-92s). The leading LNA-ASO, named MIR17PTi, impaired proliferation of several 38 
cancer cell lines (n=48) established from both solid and hematologic tumors by on-target 39 
antisense activity, and more effectively as compared to miR-17-92s inhibitors. By focusing 40 
on multiple myeloma (MM), we found that MIR17PTi triggers apoptosis via impairment of 41 
homeostatic MYC/miR-17-92 feed-forward loops (FFLs) in patient-derived MM cells; and 42 
induced MYC-dependent synthetic lethality. We show that alteration of a BIM-centered 43 
FFL is instrumental for MIR17PTi to induce cytotoxicity in MM cells. MIR17PTi exerts 44 
strong in vivo anti-tumor activity in NOD-SCID mice bearing clinically relevant models of 45 
MM, with advantageous safety and pharmacokinetics profiles in non-human primates. 46 
Altogether, MIR17PTi is a novel pharmacological tool to be tested in early-phase clinical 47 
trials against MM and other MYC-driven malignancies.48 
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Introduction 49 
MiR-17-92 is an oncogenic cluster of microRNAs (miRNAs) encoded by MIR17HG 50 
at 13q31.31,2. According to ENSEMBL genome browser (GRCh38.p10), three long non-51 
coding RNAs (lncRNAs) are produced by the alternative splicing of a MIR17HG primary 52 
transcript (MIR17HG-PT), with only lncRNAs MIR17HG-202 and MIR17HG-203 (hereafter 53 
simply referred as pri-mir-17-92) generating the six miR-17-92 mature miRNAs (miR-17-54 
92s), including miR-17/-18a/-19a/-20a/-19b-1/-92a-11,2. This cluster is steadily upregulated 55 
in solid and hematologic malignancies, mainly because of amplification of the genomic 56 
locus or by transcriptional mechanisms1,2. Based on their seed regions, miR-17-92s are 57 
grouped into four different families (miR-17, miR-18, miR-19 and miR-92), which share 58 
most target genes1,2. These latter include several tumor suppressors, such as the pro-59 
apoptotic factor BIM (also known as BCL2L11), thus explaining the tumor promoting 60 
functions of miR-17-92s1,2.  61 
A key transcriptional regulator of MIR17HG is the transcription factor c-MYC 62 
(MYC)3. This oncogene drives the onset and progression of several human malignancies, 63 
including multiple myeloma (MM)4, B-cell lymphomas (BCLs)5 and triple-negative breast 64 
cancer (TNBC)6, which carry the trait of “hard-to-treat” tumors7. miR-17-92 ensures cellular 65 
homeostasis during MYC-driven tumorigenesis by counteracting the MYC apoptotic signal. 66 
This effect is achieved by the cooperative activity of all six miR-17-92s, which coordinately 67 
fine-tune MYC expression and suppress MYC-related apoptotic program3,8. The close 68 
interplay between MYC and miR-17-92, along with the lack of therapeutic tools for the 69 
direct targeting of MYC9, underscores the relevance of  miR-17-92 as attractive druggable 70 
target in MYC-driven cancer. In this scenario, the targeting of miR-17-92 is likely to frame 71 
as a MYC-dependent synthetic lethal (SL) approach, whereby it specifically produces 72 
cytotoxicity in the presence of hyperactive/deregulated MYC10. 73 
On these basis, we hypothesized that a powerful anti-tumor effect would be 74 
achieved by inducing simultaneous downregulation of all miR-17-92s; and we developed a 75 
novel strategy that allows their “one shot” inhibition via the targeting of miR-17-92 primary 76 
transcript by RNase H-activating antisense oligonucleotides (i.e. gapmeRs). Our efforts led 77 
to the pre-clinical development as anti-cancer agent of first-in-class MIR17PTi (MIR17HG 78 
Primary Transcript inhibitor). We demonstrate its therapeutic activity in the context of MM, 79 
where MIR17PTi promotes a newly identified MYC-dependent synthetic lethality (SL) via 80 
the alteration of a BIM-centered MYC-miR-17-92 feed-forward loops (FFLs).  81 
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To our knowledge, this is the first report of “pri-miRNA therapeutics” with 82 
translational value in human cancer.83 
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Material and Methods 84 
Cells 85 
Human cell lines and primary cells were grown at 37°C, 5% CO2. Detailed information is 86 
included in Supplementary Methods section. 87 
 88 
Antisense oligonucleotides, miRNA mimics/inhibitors and shRNAs 89 
The following Long Non-Coding LNA gapmerRs were customly-designed and purchased 90 
from Exiqon (Vedbaek, Denmark): 91 
 92 
IDS, Sequence and length of seven miR-17-92 LNA gapmeRs and three controls. 93 
 
IDs 
 
SEQUENCE 5’-3’ 
 
LENGHT 
(mer) 
LNA gapmeR_02 ACATCGACACAATAA 15 
LNA gapmeR_05 TCAGTAACAGGACAGT 16 
LNA gapmeR_06 
(MIR17PTi) 
TACTTGCTTGGCTT 14 
LNA gapmeR_10 ATGCAAAACTAACAGA 16 
LNA gapmeR_12 GAAGGAAAATAGCAGGC 16 
LNA gapmeR_15 AGCACTCAACATCAGC 16 
LNA gapmeR_16 
Scr-NC (also known as 
Negative control A) 
CGACAGGCCGAAGCT 
       AACACGTCTATACGC 
15 
15 
Lp-MIR17PTi TACTTGCTTGGCTT 14 
mix-MIR17PTi 
 
TACTTGCTTGGCTT 
 
14 
 
 94 
Detailed information on other oligonucleotides used in our work is reported Supplementary 95 
Methods section. 96 
 97 
Gymnosis 98 
Cells were seeded at low plating density in order to reach confluence on the final day of 99 
the experiments (day 6). Cell number at plating ranged from 0,5 to 2,5 x 103 in 96-well 100 
plates, from 2,5 to 10 x 104 in 12-well plates and from 1 to 3 x 105 in 6-well plates.  101 
 102 
Transient and stable transfection of cells 103 
Detailed information can be found in Supplementary Methods section.  104 
 105 
CRISPR/CAS9-mediated genome editing 106 
Detailed information can be found in Supplementary Methods section.  107 
 108 
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 109 
Survival assay / detection of apoptosis / cell cycle analysis 110 
Detailed information can be found in Supplementary Methods section.  111 
 112 
Synergism quantification 113 
Detailed information can be found in Supplementary Methods section.  114 
 115 
Reverse transcription (RT) and quantitative real-time amplification (qRT-PCR) 116 
RNA extraction, reverse transcription (RT) and quantitative real-time amplification (qRT-117 
PCR) were performed as previously described11. Detailed information is included in 118 
Supplementary Methods section. 119 
 120 
Western blot analysis 121 
Protein extraction and western blot analysis were performed as previously described11. 122 
Detailed information is included in Supplementary Methods section. 123 
 124 
Confocal Microscopy 125 
Detailed information can be found in Supplementary Methods section.  126 
 127 
Gene expression profiling 128 
Detailed information can be found in Supplementary Methods section.  129 
 130 
NOD SCID mice and in vivo models of human MM 131 
Male CB-17 severe combined immunodeficient (SCID) mice (6- to 8-weeks old; Harlan 132 
Laboratories, Inc., Indianapolis) were housed and monitored in our Animal Research 133 
Facility. All experimental procedures and protocols had been approved by the Institutional 134 
Ethical Committee (Magna Graecia University) and conducted according to protocols 135 
approved by the National Directorate of Veterinary Services (Italy). Detailed information 136 
can be found in Supplementary Methods section.  137 
 138 
Immunohistochemistry (IHC) and in situ hybridization (ISH) 139 
These experiments were performed as recently described by our group12. 140 
 141 
Non-human primates study 142 
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These experiments were performed as recently described by our group12. 143 
 144 
Statistical Analysis 145 
All in vitro experiments were repeated at least three times and performed in triplicate; a 146 
representative experiment was showed in figures. Statistical significances of differences 147 
were determined using Student's t test, with minimal level of significance specified as 148 
p<0.05. Statistical significance of the in vivo growth inhibition was determined using 149 
Student's t test. The minimal level of significance was specified as p<0.05. All statistical 150 
analyses were determined using GraphPad software (http://www.graphpad.com). Graphs 151 
were obtained using GraphPad software.152 
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Results 153 
MIR17PTi prevents biogenesis of miR-17-92s 154 
MIR17HG-PT, as well as pri-mir-17-92 , is located within cell nucleus13. This environment 155 
is selectively enriched of RNase H, an enzyme that catalyzes non-specific cleavage of 156 
RNA strands within DNA/RNA hetero-duplexes14. We attempted, therefore, to induce 157 
degradation of nascent MIR17HG-PT and pri-mir-17-92 by LNA gapmeRs, a highly 158 
efficient and recently-developed class of RNase H-activating antisense oligonucleotides 159 
(ASOs) (Fig. 1a)14. We first screened LNA-modified gapmeRs for their ability to inhibit 160 
miR-17-92 cluster in transfected 293T cells: here, among seven original molecules, only 161 
gapmeR_06 and gapmeR_15 efficiently downregulated pri-mir-17-92 (Fig. 1b) and all six 162 
miR-17-92s (Fig. 1c and Supplementary Fig. 1a). Since gapmeR_06 showed higher 163 
inhibitory efficiency, it was selected for further development (hereafter named MIR17PTi). 164 
Importantly, MIR17PTi downregulated miR-17-92 cluster by activating the RNase H: in 165 
fact, chemical modifications of MIR17PTi within the RNase H-recruiting domain (the 166 
resulting oligo was named mix-MIR17PTi) abrogated its inhibitory activity (Fig. 1d); 167 
consistently, MIR17PTi failed to downregulate pri-mir-17-92 after RNAi-mediated silencing 168 
of RNase H1 (Fig. 1e). MIR17PTi also produced the downregulation of lncRNA MIR17HG-169 
201 (Supplementary Fig. 1b), a shorter transcript produced by the alternative splicing of 170 
MIR17HG-PT. This isoform does not contain the MIR17PTi-targeted sequence, confirming 171 
that MIR17HG-PT is primarily targeted by MIR17PTi.  172 
In transfection-free or “gymnotic” conditions14, the timing of pri-mir-17-92 173 
downregulation (Fig. 1f) was concomitant with nucleus entrance of a FAM-labeled 174 
MIR17PTi (Fig. 1g). We did not observe any further increase of nuclear uptake at day 6 as 175 
compared to day 4,5 (not shown), suggesting that the strongest downregulation of pri-mir-176 
17-92 observed at day 6 comes from prolonged activity of MIR17PTi in the nucleus. 177 
Importantly, downregulation of pri-mir-17-92 was followed by decrease of miR-17-92s (Fig. 178 
1h); both effects (inhibition of pri-mir-17-92 and miR-17-92s) occurred in a dose-dependent 179 
fashion (Supplementary Fig. 1c-d).  180 
These findings demonstrate that targeting of MIR17HG-PT by LNA gapmeRs 181 
prevents the biogenesis of all miR-17-92s. 182 
 183 
MIR17PTi affects proliferation of several cancer cell lines 184 
We analyzed MIR17PTi activity, by gymnotic exposure, in cancer cells; and we found that 185 
it significantly affected the in vitro growth of several cancer cell lines (n=48) established 186 
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from either solid- or hematologic- tumors (Fig. 2a). Intriguingly, the latter showed the 187 
strongest sensitivity to MIR17PTi as well as the highest pri-mir-17-92 expression within the 188 
Cancer Cell Line Encyclopedia (Supplementary Fig. 2a). MIR17PTi did not affect the 189 
proliferation of four out of five non-malignant cell lines (NM-CLs) (Fig. 2a): indeed, 190 
proliferation of THLE-2 (liver) and HK-2 (kidney) NM-CLs was not significantly affected 191 
even at concentrations up to five folds higher (50μM) than those used in this screening 192 
phase (10μM) (Supplementary Fig. 3a). By qRT-PCR analysis, we found that MIR17PTi 193 
efficiently downregulated pri-mir-17-92 and miR-17-92s both in MIR17PTi-sensitive and in 194 
MIR17PTi-resistant cells, indicating that MIR17PTi resistance did not depend on inefficient 195 
uptake of the oligo (Supplementary Fig. 3b-c). Moreover, we further confirmed this pattern 196 
of sensitivity/resistance to MIR17PTi by transfecting a subset of both CCLs and NM-CLs 197 
(Supplementary Fig. 3d). In CCLs, mix-MIR17PTi did not affect proliferation 198 
(Supplementary Fig. 3e) while LNA gapmeR-15, which downregulates both pri-mir-17-92 199 
and miR-17-92s, performed similarly to MIR17PTi (Supplementary Fig. 3f-g). 200 
We next evaluated the anti-cancer activity of MIR17PTi as compared to the 201 
individual targeting of miR-17-92s. At this end, we transfected different CCLs from 202 
hematologic malignancies (n=8) with either MIR17PTi or synthetic inhibitors for each miR-203 
17-92s; and we found, as shown in Fig. 2b, that MIR17PTi affected proliferation of all 204 
CCLs significantly more efficiently than miR-17-92s inhibitors. Importantly, the anti-205 
proliferative activity of MIR17PTi was closely reproduced by co-transfecting all miR-17-92s 206 
inhibitors (pooled miR-17-92s inhibitors; Fig. 2c); and the activity of MIR17PTi was 207 
significantly rescued by concomitant over-expression of all miR-17-92s, by either synthetic 208 
mimics or lentivectors (Fig. 2d). 209 
These findings indicate that cancer cells from different tissues, and especially those 210 
of hematologic origin, are sensitive to MIR17PTi. Moreover, they strengthen the rational of 211 
targeting the entire miR-17-92 cluster via MIR17HG-PT degradation instead of inhibiting 212 
individual mature miRNA components.  213 
 214 
MIR17PTi is highly active in primary MM cells and human myeloma cell lines 215 
Further investigation, to establish proof of concept for the potential therapeutic 216 
value of MIR17PTi, was carried out using MM as working platform. In MM patients, by 217 
querying a proprietary microarray dataset, we found that expression of pri-mir-17-92 and 218 
miR-17-92s is significantly upregulated at the most advanced stage (namely secondary 219 
plasma cell leukemia, sPCL) (Supplementary Fig. 4a). RNA-seq analysis of 320 newly-220 
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diagnosed MM patients, from IFM/DFCI 2009 clinical study (NCT0191060)15, indicated that 221 
high pri-mir-17-92 expression correlates with worse clinical outcome (OS and PFS) 222 
(Supplementary Fig. 4b), even if at this stage it is not significantly upregulated as 223 
compared to healthy donors (n=16) (not shown). These data suggested that, in MM 224 
patients, higher miR-17-92 expression is associated with a more aggressive phenotype, 225 
such as end-stage disease (sPCL) and/or poor prognosis subgroups yet to be defined. 226 
In HMCLs, we found that MIR17PTI affected proliferation in dose-dependent fashion 227 
(Fig. 3a); and the timing of this effect overlapped with downregulation of miR-17-92s 228 
(Fig.3b). Growth-inhibition was ascribed to G0/G1 cell cycle arrest (Fig. 3c and 229 
Supplementary Fig. 5), apoptosis (Fig.3c and Supplementary Fig. 6 and 7) and 230 
senescence (Fig. 3d); and was even more evident in methylcellulose-based long-term 231 
cultures, where the growth of colonies was abrogated at nanomolar concentrations (Fig. 232 
3e). Importantly, MIR17PTi was still active against HMCLs made resistant to conventional 233 
anti-MM agents, such as dexamethasone (MM.1R), melphalan (LR7), bortezomib (ABZB) 234 
or carfilzomib (ACFZ) (Fig. 3f); and survival signals from co-cultured human bone marrow 235 
stromal cells (hBMSCs) did not rescue MIR17PTi activity (Fig. 3g and Supplementary 236 
Figure 8a). Moreover, combination of MIR17PTi with dexamethasone, melphalan or 237 
bortezomib produced in most cases synergistic effects (Fig. 3h and Supplementary Fig. 238 
8b). 239 
In ex-vivo viability assays, MIR17PTi was cytotoxic to primary MM (pMM) cells 240 
derived from patients at either bone marrow microenvironment (BMM)-dependent (n=11) 241 
or BMM-independent (n=2) stage of disease (Fig. 3i; detailed information on pMM cells are 242 
reported in Supplementary Fig. 9a). Consistently with a tumor-selective killing activity, 243 
MIR17PTi did not affect viability of either CD138+ cells from patients with the pre-244 
malignant condition of monoclonal gammopathy of undetermined significance (MGUS) 245 
(n=3) (Supplementary Fig. 9b) nor PBMCs from healthy donors (n=2) (Supplementary Fig. 246 
9c). 247 
These data highlight the strong therapeutic potential of MIR17PTi against MM. 248 
 249 
MIR17PTi affects MYC transcriptional network in primary MM cells 250 
By microarray-based gene expression profiling (GEP), we explored the molecular 251 
perturbations produced by MIR17PTi in pMM cells (n=4; pt#5, pt#6, pt#7, pt#9) co-cultured 252 
with HS-5 stromal cells. Unsupervised hierarchical clustering segregated samples based 253 
on treatment, suggesting a coherent transcriptome modulation (figure 4a). Ingenuity 254 
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Pathway Analysis (IPA) of GEP data highlighted MYC as the most significantly affected 255 
upstream regulator (p=3,17E-06, not shown). Consistently, gene set enrichment analysis 256 
(GSEA)16,17 identified MYC_TARGET_V1 as the most significantly enriched Hallmark 257 
collection in the positive phenotype (i.e. genes upregulated by MIR17PTi) (Fig. 4b); and in-258 
depth analysis of the MYC_TARGET_V1 founder gene sets (n=404) showed the specific 259 
enrichment of transcriptional signatures of MYC-upregulated target genes (Fig. 4c). 260 
MIR17PTi induced similar transcriptional alterations in the highly-sensitive AMO1 cells 261 
(Supplementary Fig. 10b-c). Conversely, treatment of MIR17PTi-resistant pMM cells (n=2; 262 
pt#10, pt#11) did not alter the MYC transcriptional signaling, as assessed by GEP 263 
analysis, even if pri-mir-17-92 was significantly downregulated (not shown).  264 
To address the transcriptional changes directly produced in pMM cells after miR-17-265 
92s downregulation, we searched for miR-17-92s targets among the genes upregulated by 266 
MIR17PTi. At this aim, GEP data from MIR17PTi-sensitive pMM cells were matched with 267 
computationally predicted and CLIP-seq validated direct interactors of miR-17-92s (Fig. 268 
4d). This approach disclosed several upregulated genes (n=65) which are bona fide 269 
targets of miR-17-92s in pMM cells (Fig. 4d and Supplementary Table S1); and, 270 
consistently with a direct regulation by miR-17-92s, transduction of AMO1 or U266 with a 271 
miR-17-92s lentiviral vector produced the downregulation of some of these genes 272 
(Supplementary Fig. 11a-d). Importantly, approximately the half of these miR-17-92s direct 273 
targets presents MYC binding loci within the promoter region (28/65), and some have been 274 
already validated as transcriptional targets of MYC (15/65), even in B cells (13/65)18-22 275 
(Fig. 4e and Supplementary Table S1). GEP data were validated in pMM cells (pt#4, pt#5, 276 
pt#6) by qRT-PCR analysis of BIM, BZW2, DUSP2, NAP1L1 and VDAC1 (Fig. 4f) and in 277 
AMO1 either by qRT-PCR or western blotting (Supplementary Fig. 11e-f). 278 
These findings suggested that MIR17PTi upregulates a subset of genes which are 279 
transcriptionally regulated by MYC, pointing to the existence of a MYC/miR-17-92 co-280 
regulated network that might exert homeostatic functions in MM cells; and led us to 281 
hypothesize that MIR17PTi exerts its anti-MM activity via the redirection of a MYC-related 282 
transcriptional program towards apoptotic cell death. 283 
 284 
MIR17PTi triggers MYC-dependent synthetic lethality 285 
We investigated whether an active MYC transcriptional program sensitizes MM cells to 286 
MIR17PTi; at this aim, we transduced MYC defective U26611 with a lentiviral vector 287 
carrying the MYC open reading frame (U266MYC+) or with an empty vector (U266MYC-). 288 
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Both pri-mir-17-92 and miR-17-92s increased in U266MYC+ (Supplementary Fig. 12a), 289 
which is consistent with a MYC upstream regulation on MIR17HG also in MM cells. This 290 
assumption was further corroborated by the in silico analysis of a proprietary microarray 291 
dataset (GSE70323) that showed positive correlation between MYC and MIR17HG in MM 292 
patients (Supplementary Fig. 12b). More importantly, MIR17PTi was considerably more 293 
cytotoxic to U266MYC+ as compared to U266MYC- (Fig. 5a), supporting the idea that 294 
MIR17PTi triggers a MYC-dependent synthetic lethality (SL) in MM cells.  295 
We next explored MIR17PTi activity in P493-6 and MYC-ER HMECs cells, where 296 
MYC expression can be conditionally modulated. Specifically, P493-6 is an immortalized 297 
B-cell line carrying a tetracycline-regulated MYC23, while MYC-ER HMEC is an 298 
immortalized human mammary epithelial cell line engineered with an inducible MYC and 299 
estrogen receptor fusion protein (MYC-ER)24. These cells represent valuable experimental 300 
models of B-cell lymphomas (BCLs) and triple-negative breast cancer (TNBC), 301 
respectively, which are prototypical MYC-driven diseases5,6 where miR-17-92 is commonly 302 
upregulated25,26. Both pri-mir-17-92 and miR-17-92s increased in P493-6 and MYC-ER 303 
HMECs when MYC expression or activity, respectively, was turned on (Supplementary 304 
Fig. 12a). Again, treatment with MIR17PTi effectively induced cell death only at MYC-on 305 
cells, without any significant cytotoxicity when MYC was silenced or inactive (Fig. 5a).  306 
These data provide the formal proof that treatment with MIR17PTi is a new MYC-307 
dependent SL approach in MM and other cancers. 308 
 309 
Impairment of a BIM-centered MYC/miR-17-92 FFL mediates MIR17PTi anti-MM 310 
activity 311 
To shed light on the molecular mechanisms underlying MYC-dependent SL by MIR17PTi, 312 
we next focused on MYC/miR-17-92s co-regulated targets in MM cells; and, among them, 313 
the tumor-suppressor and pro-apoptotic factor BIM, a BH3-only BCL2-family member, 314 
appeared of particular interest. In fact, MYC positively regulates BIM transcription27 while 315 
different miR-17-92s repress its expression at post-transcriptional level1-3, thus forming a 316 
prototypical miRNA-mediated FFL28. Moreover, BIM is the primary effector of MYC-317 
induced apoptotic program in MYC-overexpressing cells27, with haplo-insufficient tumor-318 
suppressor activity in B cells18,27. Interestingly, OPM-2 and SK-MM-1, which were the only 319 
two MIR17PTi-resistant HMCLs, did not express detectable levels of BIM protein (Fig. 5b) 320 
or mRNA (not shown), likely due to epigenetic repression of its transcription (in fact, either 321 
OPM-2 nor SK-MM-1 bring deletion of BCL2L11/BIM; not shown). In hdPBMCs, which 322 
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express very low levels of BIM protein as compared to HMCLs (Fig. 5b and 323 
Supplementary Fig. 13), MIR17PTi did not increase BIM expression (Supplementary Fig. 324 
13). On the other hand, MIR17PTi strongly upregulated BIM protein in pMM cells (Fig. 5c) 325 
and different HMCLs (Fig. 5d); upregulation of BIM was also produced by co-transfection 326 
of pooled miR-17-92s inhibitors (Fig. 5e), while its protein expression was significantly 327 
reduced in AMO1 transduced with a miR-17-92s lenti-vector (Fig. 5f). More importantly, 328 
CRISPR/Cas9-mediated knock-out of BIM strongly antagonized MIR17PTi-mediated killing 329 
in both AMO1 (AMO1BIM-) and U266MYC+/BIM- generated clones (Fig. 5g-h). 330 
These results demonstrate that MIR17PTi triggers MYC-dependent SL in MM cells, 331 
in a significant part, via the impairment of a BIM-centered MYC/miR-17-92 FFL, which 332 
results in the upregulation of BIM up to pro-apoptotic level (Fig. 5i). Of course, 333 
upregulation of other miR-17-92s targets likely contributes to its activity; indeed, MIR17PTi 334 
also increased the expression of relevant tumor-suppressors such as CDKN1A (also 335 
known as p21), TP53, E2F1 or PTEN (Supplementary Fig. 13) which are validated targets 336 
of different miR-17-92s2. 337 
 338 
In vivo anti-MM activity of MIR17PTi in NOD SCID mice   339 
We investigated the in vivo activity of MIR17PTi in NOD SCID mice bearing subcutaneous 340 
(s.c.) MM xenografts (NCI-H929, AMO1luc+ and bortezomib-refractory ABZBluc+). 341 
Importantly, systemic administration (i.v.) of naked MIR17PTi significantly inhibited tumor-342 
growth (Fig. 6a; supporting BLI images are reported in Supplementary Fig. 14a-b) and 343 
prolonged animal survival (Fig. 6b), with a well-defined therapeutic window (H&E staining 344 
of accumulation organs is reported in Supplementary Fig. 15a). qRT-PCR analysis of pri-345 
mir-17-92 confirmed a productive antisense activity of MIR17PTi in retrieved tumors (Fig. 346 
6c), which also resulted in BIM upregulation at both mRNA and protein level (Fig. 6d). By 347 
in situ hybridization (ISH) analysis, using a specific LNA probe for MIR17PTi, we showed a 348 
higher uptake in kidney and liver, followed by BM, heart and lung (Supplementary Fig. 349 
15b), which is consistent with canonical LNA-modified ASO pharmacokinetics (PK)29. By 350 
this approach, MIR17PTi was also detected in retrieved tumors (Supplementary Figure 351 
15b). Next, we investigated the anti-MM activity of MIR17PTi in the clinically-relevant 352 
SCID-hu model30, which allows the in vivo growth of BM-dependent MM cells within a 353 
recapitulated human bone marrow milieu: in this model, MIR17PTi elicited a strong anti-354 
MM activity, as assessed by measurement of soluble IL-6R levels in the plasma of treated 355 
vs untreated mice (Fig. 6e).  356 
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These data demonstrate a relevant in vivo anti-MM activity of MIR17PTi as single 357 
agent, even capable to overcome the protective effects of the bone marrow milieu. 358 
 359 
Safety and PK profile of MIR17PTi in non-human primates  360 
We investigated the safety and plasmatic pharmacokinetics (PK) of MIR17PTi in non-361 
human primates (non-naïve cynomolgus monkeys). The amount per injection was 362 
equivalent to the amount administered to NOD SCID mice, after inter-species dose 363 
conversion31. To assess the safety profile, MIR17PTi was injected on days 1-4-8-15-22 364 
(same schedule used in mice) and, as control, an additional animal was i.v. injected with 365 
saline solution. At the end of treatment period, no signs of toxicity could be recorded 366 
(Supplementary Fig. 16-17). MIR17PTi was then i.v. injected as single dose in a third 367 
animal, in order to explore the plasmatic PK profile. Plasma was collected at following 368 
time-points: pre-dose, 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 12 hrs, 24 hrs and 48 hrs. Plasmatic 369 
MIR17PTi, as detected by PNA-HPCL assay, peaked at a Tmax of 0.5 hr with a Cmax of 370 
2,638 ng/mL (Fig. 7a). Compared with the 28,473 hr * ng/mL value of area under the 371 
concentration-time curve (AUC0-∞), the 21,994 hr * ng/mL value of AUC0-12 indicated that 372 
more than 75% of MIR17PTi left the plasma within 12 hrs (Fig. 7b). These findings were 373 
consistent with the favorable PK profile of LNA-modified ASOs, which assumes rapid 374 
plasmatic clearance via tissue uptake12,29.375 
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Discussion 376 
We developed and here described a new strategy for the therapeutic targeting of miRNA 377 
network in human cancer. This approach exploits RNase H-activating LNA gapmeRs to 378 
induce the degradation of miRNA primary transcripts (pri-miRNA) and, consequently, to 379 
prevent the biogenesis of related mature miRNAs. Recent evidence demonstrated that 380 
these third-generation ASOs predominantly act on nascent primary transcripts (nascent 381 
pri-miRNAs in this study) before being processed by the splicing machinery32,33. As 382 
compared to canonical miRNA inhibitors, LNA gapmeRs better adapt to the targeting of 383 
miRNA clusters: in this case, indeed, degradation of pri-miRNAs leads to the concomitant 384 
downregulation of all miRNA members of the cluster. On these premises, we identified the 385 
miR-17-92 cluster as a target with high translational value in the context of human cancer3; 386 
and, among different originally-designed LNA gapmeRs, we selected MIR17PTi for its 387 
antisense activity. Consistent with our initial hypothesis, MIR17PTi efficiently 388 
downregulates pri-mir-17-92 and all miR-17-92s in RNase H-dependent manner; by 389 
contrast, we failed to induce these effects via RNAi, possibly due to the absence or 390 
alternative functions of RNAi machinery within cell nucleus34,35. Our study spanned from 391 
conceptual drug design to pre-clinical investigation in non-human primates. 392 
Previous reports suggested that oncogenicity of miR-17-92 may be confined to one 393 
or few miRNAs in specific cellular contexts36, thus supporting the rational design of miR-394 
17-92s-based therapeutic strategies. Our data, indeed, confirm that CCLs may be 395 
differently addicted to miR-17-92 members; however, they rather support the potential 396 
advantage of concomitant downregulation of the entire cluster at least in hematologic 397 
cancers. In fact, MIR17PTi antagonized the proliferation of hematologic CCLs more 398 
efficiently than synthetic inhibitors of miR-17-92s. Moreover, hematologic CCLs from the 399 
same malignancy such as MCL or MM were differently sensitive to the inhibition of each 400 
miR-17-92s, making very likely the failure of a miRNA-based therapeutic approach in the 401 
context of the intra-/inter-clonal heterogeneity which features human cancer37,38. Actually, 402 
our results can be explained taking into account that miR-17-92s have redundant functions 403 
because of the sharing of most of the mRNA targets: it is reasonable that, upon individual 404 
antagonism of each cluster member, the remaining miR-17-92s could act by compensatory 405 
mechanisms. Moreover, it must be noted that MIR17PTi also induces the downregulation 406 
of lncRNAs MIR17HG-201/-202/-203, pre-mir-17-92s (pre-mir-17/-18a/-19a/-20a/-19b/-407 
92a) and miR-17-92s complementary strands (miR-17-3p/ miR-18a-3p/ miR-19a-5p/ miR-408 
20a-3p/ miR-19b-5p/ miR-92a-5p) that are potentially endowed with own functions; and 409 
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can contribute to MIR17PTi anti-cancer activity. This possibility is also suggested by the 410 
incomplete rescue obtained by enforcing the expression of all miR-17-92s. However, this 411 
point has not been addressed in our work and requires further investigation.  412 
We used MM, a MYC-driven malignancy of terminally-differentiated B cells (i.e. 413 
plasma cells)39, as the main investigational platform for the pre-clinical development of 414 
MIR17PTi. In a proprietary RNA-seq dataset of 320 newly-diagnosed MM patients, we 415 
disclosed the association of high pri-mir-17-92 levels with worse clinical outcome. In vitro, 416 
MIR17PTi efficiently killed HMCLs and pMM cells, even co-cultured with hBMSCs and/or 417 
HS-5. At molecular level, we found that the induction of a MYC-related and pro-apoptotic 418 
transcriptional network underlies the anti-MM activity of MIR17PTi. We explained this 419 
outcome by hypothesizing that MIR17PTi impairs a functional interplay between MYC and 420 
miR-17-92, which follows the general scheme of homeostatic miRNA-mediated FFLs28,40; 421 
and we formally proved our hypothesis by demonstrating that an active MYC downstream 422 
signaling, achieved by enforcing MYC expression (U266MYC+ or P493-6DOX-) or activity 423 
(MYC-ER HMECTAM+), strongly sensitizes to MIR17PTi killing. We explored the molecular 424 
mechanisms underlying this synthetic lethal effect in MM cells by focusing on MYC/miR-425 
17-92s co-regulated targets. Specifically, the tumor suppressor BIM gained our attention 426 
given its established role as the primary effector of MYC apoptotic program18,27. The 427 
finding that MIR17PTi-resistant MM cells (i.e OPM2 and SK-MM-1) did not express 428 
detectable BIM protein/mRNA prompted us to investigate MIR17PTi activity in HMCLs 429 
after BIM knock-out (i.e. AMO1BIM- and U266MYC+/BIM-); and in these experimental 430 
conditions the killing activity of MIR17PTI was strongly antagonized. On these basis, we 431 
speculate that MYC/miR-17-92 FFLs are required to maintain the expression of BIM, and 432 
likely other co-regulated genes, at homeostatic levels that allow MM cells to proliferate; 433 
and we conclude that MIR17PTi triggers MYC-dependent synthetic lethality by affecting 434 
these homeostatic FFLs, resulting in the upregulation of BIM (and likely other genes) over 435 
a homeostatic threshold at levels prompting MM cells towards apoptosis. Overall, this 436 
mechanism is likely to occur specifically in cancer cells, where oncogenic MYC controls 437 
the transcription of apoptotic genes; it is known, in fact, that this transcriptional activity is 438 
not relevant when MYC is expressed within a physiologic range41. 439 
 MIR17PTi antagonized in vivo growth of human MM cells as single agent. This was 440 
demonstrated in four different and clinically relevant murine models, including those 441 
refractory to conventional anti-MM agents (ABZB) and those in which MM cells grow within 442 
a recapitulated human bone marrow microenvironment (i.e. SCID-hu)30. Moreover, the 443 
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potential therapeutic benefit of treatment with MIR17PTi was further corroborated by its 444 
synergistic anti-MM activity in combination with conventional and clinically-active agents, 445 
such as dexamethasone, melphalan or bortezomib. These data indeed provide the rational 446 
framework for the design of novel MIR17PTi-based drug combinations for the treatment of 447 
MM patients.  448 
To our knowledge this is the first report of pri-miRNA therapeutics with translational 449 
value for cancer therapy. We believe that this study opens a new avenue for targeting the 450 
miRNA network in human cancer, and provides with MIR17PTi a powerful weapon against 451 
MM and other hard-to-treat MYC-driven tumors.  452 
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Figures & Figure legends 577 
 578 
Fig. 1. Development of MIR17PTi 579 
(a) Cartoon summarizing the activity of LNA gapmeRs on miR-17-92 cluster. 580 
(b) qRT-PCR analysis of pri-mir-17-92 expression in 293T two days after transfection with 581 
miR-17-92 LNA gapmeRs or scr-NC (25nM).  582 
(c) qRT-PCR analysis of miR-17-92s in 293T two days after transfection with mir-17-92 583 
LNA gapmeRs or scr-NC (25nM).  584 
(d) qRT-PCR analysis of pri-mir-17-92 expression in 293T two days after transfection with 585 
mix-MIR17PTi or scr-NC (25nM).  586 
(e) qRT-PCR analysis of pri-mir-17-92 (left) and western blotting of RNASE H1 (right) in 587 
293T co-transfected with either siRNAs targeting RNASE H1 (siRNASE H1, 25nM) or 588 
scrambled siRNAs (siCNT, 25nM) and MIR17PTi or scr-NC (25nM) (three days time point). 589 
The results of qRT-PCR analysis are average pri-mir-17-92 expression levels after 590 
normalization with GAPDH and ΔΔCt calculations. GAPDH was used as protein loading 591 
control. 592 
(f) qRT-PCR analysis of pri-mir-17-92 in 293T during a time-course exposure (day 1,5-3-593 
4,5-6, every 36 hours) to MIR17PTi or scr-NC (10µM). The results are average expression 594 
levels after normalization with GAPDH and ΔΔCt calculations.  595 
(g) Confocal microscopy analysis of 293T after three days or four days and half of 596 
exposure to FAM-labeled MIR17PTi (10µM). Cell nuclei are evidenced by DAPI staining.  597 
(h) qRT-PCR analysis of miR-17-92s in 293T during a time-course exposure (day 1,5-3-598 
4,5-6, every 36 hours)) to MIR17PTi or scr-NC (10µM). The results are average 599 
expression levels after normalization with RNU44 and ΔΔCt calculations.  600 
Data from 1 out of 3 independent experiments is shown in each panel. *indicates p<0.0  601 
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Fig. 2. In vitro anti-cancer activity of MIR17PTi 602 
(a) CCK-8 assay of cancer cell lines (CCLs, n=48) and non-malignant cell lines (NM-CLs, 603 
n=5) exposed for six days to MIR17PTi or scr-NC (10µM). Data are represented as 604 
percentage of MIR17PTi-treated live cells (absorbance), as compared to scr-NC. Dashed 605 
lines indicate 20% (upper line) and 80% (bottom line) growth inhibition.  606 
(b) CCK-8 proliferation assay of eight CCLs (P3HR1 (DLBCL); SULTAN (BL); JeKo-1, 607 
Maver (MCL); AMO1, KMS-12-BM, NCI-H929, RPMI-8226 (MM)) transfected with 608 
indicated miRNA inhibitors or MIR17PTi (25nM). Data are represented as compared 609 
(percentage) to live cells after scr-NC transfection. 610 
(c) CCK-8 proliferation assay of RPMI-8226 and AMO1 after transfection with miR-NC-611 
inhibitors (150nM) or pooled miR-17-92s inhibitors (25nM each) or scr-NC (25nM) or 612 
MIR17PTi (25nM). Data are represented as compared (percentage) to live cells after mock 613 
(RNase-free water) transfection. 614 
(d) CCK-8 proliferation assay of: (left panel) AMO1 two days after co-transfection with scr-615 
NC (5nM or 25nM; showed as single point since no difference was detected in percentage 616 
of live cells) or MIR17PTi (5nM or 25nM) and miR-NC-mimics (60nM) or pooled miR-17-617 
92s mimics (10nM each); (right panel) AMO1 transduced with an empty lentiviral vector or 618 
a miR-17-92s lentiviral vector and then exposed for six days to scr-NC or MIR17PTi 619 
(0.5µM). 620 
Data from 1 out of 3 independent experiments is shown in each panel. *indicates p<0.05 621 
NM-CLs= non malignant cell lines; NSCLC= non small cell lung cancer; BC= breast 622 
cancer; PC= pancreatic cancer; MPM= malignant pleural mesothelioma; AML= acute 623 
myeloid leukemia; TCL= T cell leukemia; BL= Burkitt lymphoma; DLBCL= diffuse large B 624 
cell lymphoma; MCL= mantle cell lymphoma; MM= multiple myeloma. 625 
  626 
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Fig. 3. In vitro activity of MIR17PTi in HMCLs and pMM cells 627 
(a) Dose-dependent activity of MIR17PTi (six days time point) in HMCLs (n=10) as 628 
assessed by CCK-8 proliferation assay. Live cells are represented as compared 629 
(percentage) to untreated controls. 630 
(b) Time-dependent activity of MIR17PTi (1µM) in AMO1, as assessed by qRT-PCR 631 
analysis of (left panel) pri-mir-17-92 and (mid panel) miR-17-92s. The results shown are 632 
average pri-mir-17-92 or miRNAs expression levels after normalization with GAPDH or 633 
RNU44 and ΔΔCt calculation (expressed as percentage). Time-dependent activity of 634 
MIR17PTi (1µM) in AMO1, as assessed by CCK-8 assay (right pane).  635 
(c) Cell cycle analysis of AMO1 exposed for six days to MIR17PTi (1 µM) or sc-NC (1 µM). 636 
(d) Flow cytometry analysis of senescent AMO1 cells (β-Galactosidase positive) exposed 637 
for six days to MIR17PTi (1µM) o scr-NC (1µM). 638 
(e) Methylcellulose clonogenic assay of AMO1 exposed to MIR17PTi (1µM) o scr-NC 639 
(1µM) (two weeks time point). 640 
(f) CCK-8 proliferation assay of HMCLs sensitive (MM.1S, U266, AMO1) or resistant 641 
(MM.1R, LR7, ABZB, ACFZ) to conventional anti-MM agents (dexamethasone, melphalan, 642 
bortezomib, carfilzomib) exposed to different concentrations of MIR17PTi for six days.  643 
(g) CCK-8 assay of hBMSCs, AMO1 or AMO1 co-cultured with hBMSCs after six days of 644 
exposure to indicated concentrations of MIR17PTi. 645 
(h) Table showing combination indexes (CI) resulting from combinatorial treatments of 646 
AMO1 with MIR17PTi and dexamethasone or melphalan or bortezomib (six days time 647 
point).  648 
(i) Flow-cytometry analysis of 7-AAD stained pMM cells (n=13) exposed for eight days to 649 
MIR17PTi or scr-NC (2,5µM). pMM cells were cultured adherent to GFP+ HS-5 stromal 650 
cells (pt#1-3, patients with intra-medullary disease) or physically separated from HS-5 by 651 
membranes (pt#4-11, patients with intra-medullary disease) or alone (pt#12-13, patients 652 
with extra-medullary disease at relapse, sPCL). In the lower panel (within the frame) it is 653 
represented median activity of MIR17PTi in sensitive pMM cells (n=10) from the left panel. 654 
*indicates p<0.05  655 
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Fig. 4. Molecular perturbation induced by MIR17PTi in pMM cells 656 
(a) Hierarchical clustering of pMM cells (n=4, pt#5, pt#6, pt#7, pt#9) exposed for six days 657 
to MIR17PTi (2,5 µM) or equimolar scr-NC.  658 
(b) Table of gene sets, from the Hallmark collection, enriched of genes upregulated by 659 
MIR17PTi (positive phenotype) in sensitive pMM cells (pt#5, pt#6, pt#7, pt#9). Number of 660 
genes in each set (size), the normalized enrichment score (NES), and test of statistical 661 
significance (FDR q value) are highlighted.  662 
(c) Enrichment plots of three representative transcriptional signatures of MYC upregulated 663 
target genes in the positive phenotype of sensitive pMM cells exposed to MIR17PTi 664 
(2.5µM) for six days.  665 
(d) Venn diagram intersecting genes upregulated by MIR17PTi with genes predicted as 666 
miR-17-92s targets (by miRcode) and genes validated as miR-17-92s interactors in CLIP-667 
seq experiments (starBase v2.0).  668 
(e) Representation of MYC/miR-17-92 FFLs. In red are reported genes with a fold change 669 
(FC) increase >1.5.  670 
(f) qRT-PCR analysis of pri-mir-17-92 and BIM, BZW2, DUSP2, NAP1L1 or VDAC1 671 
mRNAs in pMM cells (n=3) exposed to MIR17PTi (2.5µM) for six days. The results shown 672 
are average pri-mir-17-92 or mRNAs expression levels after normalization with GAPDH 673 
and ΔΔCt calculations.  674 
*indicates p<0.05. 675 
  676 
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Fig. 5. Molecular mechanism underlying MIR17PTi pro-apoptotic activity 677 
(a) 7-AAD flow cytometry assay in: (left panel) U266MYC-/U266MYC+ after six days of 678 
treatment with MIR17PTi (2,5 µM) or scr-NC (2,5 µM); it is reported western blotting of 679 
MYC protein in U266MYC- and U266MYC+. GAPDH was used protein loading control. (mid 680 
panel) P493-6 after six days of treatment with MIR17PTi (2,5 µM) or scr-NC (2,5 µM), in 681 
presence or absence of doxycycline (dox); it is reported western blotting of MYC protein in 682 
P493-6 cultured for two days with or without doxycycline. GAPDH was used protein 683 
loading control. (right panel) Trypan blue exclusion staining in MYC-ER HMECs two days 684 
after transfection with MIR17PTi (50nM) or scr-NC (50nM), and cultured with or without 685 
tamoxifen (tam).  686 
(b) Western blotting of BIM in lysates from hdPBMCs (n=2), Jeko-1 (MCL, BIM-null), 687 
Daudi, Raji (BL) and indicated HMCLs. GAPDH was used as protein loading control.  688 
(c) Western blot analysis of BIM in lysates from pMM cells (pt#12 / #13, extra-medullary 689 
MM) exposed to MIR17PTi for six days at indicated concentrations. GAPDH was used as 690 
protein loading control. 691 
(d) Western blotting of BIM in AMO1, NCI-H929 or INA-6 exposed for six days to 692 
MIR17PTi (AMO1=1µM, NCI-H929 and INA-6=2.5µM) or equimolar scr-NC. GAPDH was 693 
used as protein loading control.  694 
(e) Western blot analysis of BIM in lysates from AMO1 transfected with miR-NC inhibitor 695 
(150nM) or pooled miR-17-92s inhibitors (25nM each) (two days time point). GAPDH was 696 
used as protein loading control. 697 
(f) Western blot analysis of BIM in lysates from AMO1 transduced with an empty lentiviral 698 
vector or a miR-17-92s lentiviral vector. GAPDH was used as protein loading control. 699 
(g) Western blot analysis of BIM (upper panel) and flow cytometry analysis of 7-AAD 700 
stained cells (lower panel) in CRISPR/CAS9 genome-edited AMO1BIM- cells. GAPDH was 701 
used as protein loading control. Flow-cytometry was performed after six days of exposure 702 
to MIR17PTi (1µM) o scr-NC (1µM) 703 
(h) Western blot analysis of BIM (upper panel) and flow cytometry analysis of 7-AAD 704 
stained cells (lower panel) in CRISPR/CAS9 genome-edited U266MYC+/BIM- cells. GAPDH 705 
was used as protein loading control. Flow-cytometry was performed after six days of 706 
exposure to MIR17PTi (2.5µM) o scr-NC (2.5µM) 707 
(i) Proposed model of MYC/miR-17-92 FFLs and MIR17PTi mechanism of action in MM 708 
cells. TR=transcriptional regulation; PTR=post-transcriptional regulation. 709 
Data from 1 out of 3 independent experiments is shown in each panel. *indicates p<0.05 710 
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Fig. 6. In vivo anti-MM activity of MIR17PTi  711 
(a) In vivo growth-inhibition of NCI-H929, AMO1luc+ or ABZBluc+ s.c. xenografts by 712 
MIR17PTi (2mg/kg). Treatments were performed on days 1-4-8-15-22 (NCI-H929) or 1-4-713 
8-11 (AMO1luc+ and ABZBluc+). Mice were also treated with bortezomib (BZB) as positive 714 
control (1mg/kg on days 1-4-8-11). Number of xenografted mice: NCI-H929=17 (NT=7, 715 
MIR17PTi=10); AMO1luc+=13 (NT=5, MIR17PTi=5, BZB=3); ABZBluc+=12 (NT=4, 716 
MIR17PTi=5, BZB=3). Treatments were performed systemically (i.v.). In figure are reported 717 
the tumor volumes at day 33 (NCI-H929) or day 12 (AMO1luc+ and ABZBluc+) after the first 718 
treatment. Supporting images and BLI measurements are shown in Supplementary Fig. 719 
S14. 720 
(b) Survival curves (Kaplan–Meier) relative to mice reported in Fig. 6A (log-rank 721 
test, P <0.05). Survival was evaluated from the first day of treatment until death or 722 
sacrifice. Percentage of mice alive is shown. 723 
(c) qRT-PCR analysis of pri-mir-17-92 in retrieved NCI-H929 (n=3) or AMO1luc+ (n=1) s.c. 724 
xenografts two days after the last dose of the treatment period with MIR17PTi (on days 1-725 
4-8-11), as compared to tumor retrieved from untreated animals (NCI-H929, n=1; AMOluc+, 726 
n=1). Animals used for this analysis were not considered for tumor-growth and survival 727 
evaluations. The results shown are average pri-mir-17-92 expression levels after 728 
normalization with GAPDH and ΔΔCt calculations.  729 
(d) qRT-PCR analysis (left panel) and western blotting (right panel) of BIM in retrieved 730 
tumors (AMO1) from MIR17PTi treated (n=1) or untreated (n=1) mice. The qRT-PCR 731 
results shown are average BIM expression levels after normalization with GAPDH and 732 
ΔΔCt calculations. GAPDH was used as protein loading control. 733 
(e) Schematic representation of SCID-hu model (left panel) and INA-6 growth within 734 
human fetal bone chips s.c. implanted in NOD SCID mice (right panel). Plasmatic levels of 735 
soluble IL-6R were used to evaluate tumor growth. Systemic treatments with MIR17PTi 736 
(2mg/kg, days 1-4-8-15-22) started at day 22. Effects of MIR17PTi were evaluated at the 737 
end of treatments (day 44). A total of 8 mice was used as follows: NT (n=4), MIR17PTi 738 
(n=4). 739 
*indicates p<0.05  740 
  741 
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Fig. 7. Pharmacokinetics profile of MIR17PTi in Cynomolgus Monkeys  742 
(a) Plasmatic PK profile (left panel) of MIR17PTi after injection of a Cynomolgus monkey 743 
with a single dose (0.504mg/kg). Sampling was performed at the time points indicated in 744 
the table (right panel).  745 
(b) Plasmatic PK parameters of MIR17PTi in Cynomolgus monkeys. 746 
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